Lynas share price: what to watch after a late-Friday filing before ASX trade resumes

Lynas share price: what to watch after a late-Friday filing before ASX trade resumes

Sydney, Jan 25, 2026, 17:23 AEDT — Market closed

  • After Friday’s close, Lynas will pause trading for an extended break as the ASX remains closed Monday in observance of Australia Day
  • A late Friday filing revealed a shift in a major stake in the rare earths producer
  • After a sharp move this month, investors are zeroing in on production stability and rare-earth prices

Lynas Rare Earths Ltd shares closed Friday at A$16.86, marking a 0.66% gain following a choppy session that saw prices fluctuate between A$17.79 and A$16.77.

Timing is key. Australia’s primary exchange shuts Monday for Australia Day, extending the pause until the next session. Investors will have extra time to digest filings and sector updates ahead of trading.

Late Friday, an exchange notice revealed a “change in substantial holding” for Lynas filed after the market closed. In Australia, a “substantial holder” typically means an investor owning 5% or more of a company’s shares, and any changes must be reported. Australian Securities Exchange

The filing follows Lynas’ December-quarter update earlier this week, which highlighted a mixed picture: better sales and pricing, but some operational setbacks. The company reported quarterly gross sales revenue of A$201.9 million and total rare earth oxide (REO) output at 2,382 tonnes, including 1,404 tonnes of NdPr (neodymium-praseodymium, a key magnet material for EVs and wind turbines). Lynas closed the quarter with A$1.03 billion in cash and short-term deposits. It also revealed plans to explore off-grid power solutions after disruptions at its Kalgoorlie plant impacted production.

Lynas’s recent surge offers a snapshot of investor sentiment on non-China supply. It also raises the question: do tougher operating conditions push prices up, or simply drive costs higher?

Management turnover remains a quiet concern. CEO and managing director Amanda Lacaze is set to retire at the end of the financial year, the company confirmed, with the board already conducting a search for her replacement.

Sell-side opinions remain mixed. According to TipRanks data from Friday, Bell Potter stuck with a “sell” rating but nudged its price target up to A$11.15 — still about 34% under Friday’s closing price. TipRanks

The debate heats up around that gap. Bulls point to the strategic angle and potential upside if NdPr pricing surprises on the high side. Bears, however, repeatedly flag execution risks and fret over what could unfold if prices slip even slightly.

The downside is clear-cut: additional power outages in Western Australia, a sluggish rebound at the Malaysian facility post-maintenance, or hold-ups in growth projects could drag volumes down and push the market toward a steeper cost structure.

The market was closed Monday, so all eyes turn to Tuesday’s reopening. Investors will be watching closely to see if the late-Friday holding notice signals normal register shifts or if big players are making significant moves in or out of Lynas at these prices.

Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech. His coverage ranges from stocks and technology to economic developments across global markets. He worked in investment research and market analysis before becoming a financial journalist and is a graduate of the Lahore University of Management Sciences (LUMS).

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong Buy

NVIDIA

94/100
#2 Strong Buy

Meta Platforms

89/100
#3 Buy

Alphabet

87/100
#4 Buy

Amazon

84/100
#5 Selective Buy

Microsoft

82/100
View full portfolio
Editorial model selection. Not personalised advice.
Roche stock price holds near a 52-week high as Jan. 29 results near — what to watch next week
Previous Story

Roche stock price holds near a 52-week high as Jan. 29 results near — what to watch next week

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday
Next Story

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday